{"entity":{"id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","aka":[],"tldr":"A phase 2 trial of EMB-01 1600 mg administered once weekly throughout the study in colorectal cancer, run by Shanghai EpimAb Biotherapeutics Co., Ltd., now recruiting.","summary":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT07314294 by Shanghai EpimAb Biotherapeutics Co., Ltd., with 54 participants planned, started 2025-12-18 and due to reach its primary completion in 2027-12-30. Interventions recorded: EMB-01 1600 mg administered once weekly throughout the study and EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07314294","url":"https://clinicaltrials.gov/study/NCT07314294"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07314294","phase":"2","setting":"A Randomized, Open-label, Phase II Study of EMB-01 in Patients With Recurrent/Metastatic Colorectal Cancer","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","enrolled":54,"outcomes":[]},"route":"/trials/nct07314294/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}